On November 11, 2026 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapies, reported the grant of a new patent (number 12,788,796) entitled "Combined Preparations for the Treatment of Cancer or Infection" by the United States Patent and Trademark Office (USPTO).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
With this latest grant, Immutep now holds five United States patents within this patent family. The portfolio has expanded progressively through a series of patents granted in December 2020, March 2021, June 2023, July 2026 and, most recently, this latest patent.
The claims of the new patent build on the protection provided by the four previously granted patents and are directed to combined preparations and pharmaceutical compositions comprising eftilagimod alfa ("efti") and a PD-1 pathway inhibitor. Specifically, the claims encompass combinations with BMS-936559, durvalumab, atezolizumab and avelumab. The expiry date of the patent is 23 March 2038 (including 806 days of patent term adjustment).
The patent grant provides additional protection for the use of efti in combination with PD-1 pathway inhibitors, a key class of immunotherapies used in modern cancer treatment, further expanding Immutep’s patent portfolio covering efti-based combination therapies. Immutep has also filed a continuation application to pursue additional embodiments of the invention.
Marc Voigt, CEO of Immutep, said: "We are pleased to receive this latest US patent grant, which further strengthens the intellectual property protection surrounding efti. As we pursue our focused development strategy for efti, a good patent portfolio remains an important strategic asset, supporting future development and partnering opportunities. We believe in the potential of this unique biomolecule and that carefully selected clinical settings could provide meaningful opportunities for continued evaluation and value creation."
About Eftilagimod Alfa (Efti)
Eftilagimod alfa (efti) is Immutep’s proprietary soluble LAG-3 protein and MHC Class II agonist that activates antigen-presenting cells through the MHC Class II pathway, engaging both innate and adaptive immunity, including the priming of cytotoxic CD8+ T cells and the production of co-stimulatory signals and cytokines. Its favourable safety profile enables combination with anti-PD-(L)1 therapy, radiotherapy and/or chemotherapy. Efti has received Fast Track designation from the U.S. Food and Drug Administration in first-line head and neck squamous cell carcinoma and first-line non-small cell lung cancer, and Orphan Drug Designation in soft tissue sarcoma.
(Press release, Immutep, NOV 11, 2026, View Source [SID1234674630])